journal
MENU ▼
Read by QxMD icon Read
search

Current Treatment Options in Oncology

journal
https://www.readbyqxmd.com/read/28861885/erratum-to-clinical-impact-of-the-2016-update-to-the-who-lymphoma-classification
#1
Ryan C Lynch, Dita Gratzinger, Ranjana H Advani
No abstract text is available yet for this article.
October 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28921484/reply-to-the-letter-by-s-sorscher-regarding-implications-of-braf-mutations-in-dmmr-colorectal-cancers
#2
REVIEW
R Cohen, T André
ᅟ.
September 18, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28921419/sentinel-lymph-node-biopsy-in-endometrial-cancer-a-new-standard-of-care
#3
REVIEW
Stephanie A Sullivan, Emma C Rossi
Lymph node status is one of the most important factors in determining prognosis and the need for adjuvant treatment in endometrial cancer (EMCA). Unfortunately, full lymphadenectomy bears significant surgical and postoperative risks. The majority of patients with clinical stage I disease will not have metastatic disease; thus, a full lymphadenectomy only increases morbidity in this population of patients. The use of the sentinel lymph node (SLN) biopsy has emerged as an alternative to complete lymphadenectomy in EMCA...
September 18, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28913767/management-of-atypical-renal-cell-carcinomas
#4
REVIEW
Bobby C Liaw, Reza Mehrazin, Charles Baker, John P Sfakianos, Che-Kai Tsao
Non-clear cell renal cell carcinoma (RCC) encompasses a diverse group of diseases, with research yielding different histologic findings and genetic profiles with each distinct subgroup. Simply mirroring the management techniques of clear cell RCC and borrowing from its growing armamentarium of therapeutic agents, while somewhat productive at first, but will ultimately be limiting. Further investigation into the molecular pathogenesis of disease, similarities and differences between specific subtypes, and mechanisms of resistance to therapeutics will help identify new targets, stimulate development of novel agents, and improve clinical trial offerings for non-clear cell RCC (nccRCC)...
September 14, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28840513/fertility-sparing-strategies-in-patients-affected-by-placental-site-trophoblastic-tumor
#5
REVIEW
Benito Chiofalo, Vittorio Palmara, Antonio Simone Laganà, Onofrio Triolo, Salvatore Giovanni Vitale, Francesca Conway, Giuseppe Santoro
Placental site trophoblastic tumor (PSTT) is the least common and the most ambiguous gestational trophoblastic tumor. Presentation of PSTT may occur in the course of gestation or from 1 week to 14 years after a normal or an abnormal pregnancy (mole, ectopic pregnancy, abortion). The indicators of aggressive behavior for this tumor are not well established. Due to the rarity of this disease that usually affects women of childbearing potential, we aimed to review the current literature, to identify risk factors and the best conservative therapeutic choices among the cases described...
August 24, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28840453/immunotherapy-in-gynecologic-cancers-are-we-there-yet
#6
REVIEW
Janelle B Pakish, Amir A Jazaeri
Immune-targeted therapies have demonstrated durable responses in many tumor types with limited treatment options and poor overall prognosis. This has led to enthusiasm for expanding such therapies to other tumor types including gynecologic malignancies. The use of immunotherapy in gynecologic malignancies is in the early stages and is an active area of ongoing clinical research. Both cancer vaccines and immune checkpoint inhibitor therapy continue to be extensively studied in gynecologic malignancies. Immune checkpoint inhibitors, in particular, hold promising potential in specific subsets of endometrial cancer that express microsatellite instability...
August 24, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28795312/treatment-of-lung-carcinosarcoma-and-other-rare-histologic-subtypes-of-non-small-cell-lung-cancer
#7
REVIEW
Han Yang, Yongbin Lin, Ying Liang
Lung carcinosarcoma (PCS) and other histological subtypes of non-small cell lung cancer, such as primary pulmonary lymphoma (PPL), pulmonary carcinoid (PC), and primary pulmonary lymphoepithelioma-like carcinoma (LELC), are rare. For their low incidence, the diagnosis and treatment are still controversial. Some patients only need surgery, while others may need chemotherapy, radiotherapy, or targeted therapy. In this paper, we retrospectively reviewed the literature of some rare histological subtype of NSCLC for the recent 20 years, and try to get some conclusions...
August 10, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28795297/letter-to-the-editor-implications-of-braf-mutations-in-dmmr-colorectal-cancers
#8
REVIEW
Steven Sorscher
No abstract text is available yet for this article.
August 10, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28795288/novel-agents-in-the-treatment-of-thymic-malignancies
#9
REVIEW
Claire Merveilleux du Vignaux, Jean-Michel Maury, Nicolas Girard
The management of thymic tumours is a paradigm of multidisciplinary collaboration. Chemotherapy may be administered part of curative-intent sequential strategy integrating subsequent surgery or radiotherapy, or as an exclusive treatment if local treatment is not achievable. Recurrences of thymic epithelial tumors should be managed according to the same strategy as newly diagnosed tumors. Given the limited activity of cytotoxic agents in the advanced, refractory setting, novel and innovative agents are needed...
August 10, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28795287/recent-advances-in-the-classification-and-treatment-of-ependymomas
#10
REVIEW
Heather Leeper, Michelle M Felicella, Tobias Walbert
Ependymomas are a subgroup of ependymal glia-derived neoplasms that affect children as well as adults. Arising within any CNS compartment, symptoms at presentation can range from acute onset due to increased intracranial pressure to insidious myelopathy. The overall survival (OS) outcomes in adult patients across the subgroups is heterogeneous with subependymoma having an excellent prognosis often even in the absence of any treatment, whereas supratentorial ependymomas tend to be higher grade in nature and may have an OS of 5 years despite gross total resection and adjuvant radiation...
August 10, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28795286/diagnostic-and-therapeutic-strategies-for-patients-with-malignant-epidural-spinal-cord-compression
#11
REVIEW
Dilan A Patel, Jian L Campian
Malignant epidural spinal cord compression (MESCC) is an oncologic emergency with the potential for devastating consequences for patients if not promptly diagnosed and treated. MESCC is diagnosed by imaging. MRI is by far the most sensitive test, preferably with gadolinium. Once the diagnosis of MESCC is suspected, patients with neurologic deficits should receive prompt administration of dexamethasone with a 10-mg IV loading dose followed by 4 mg every 6 h. Quick taper is recommended once the definitive treatment is established...
August 10, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28795284/dermatofibrosarcoma-protuberans
#12
REVIEW
Alvaro E Acosta, Catalina Santa Vélez
Dermatofibrosarcoma protuberans (DFSP) is a slow growing tumor with a very low metastatic potential but with significant subclinical extension and great capacity for local destruction. Thus, the first surgeon approached with such challenging tumor must attempt to cure the patient with a method that spares healthy tissue and ensures an optimal oncological, functional, and esthetic result. The treatment of DFSP often requires a multidisciplinary approach. Depending on location, dermatologic surgeons, surgical oncologists, head and neck surgeons, neurosurgeons, plastic surgeons, and occasionally medical oncologists may be involved with the management...
August 10, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28785997/clinical-trials-investigating-immune-checkpoint-blockade-in-glioblastoma
#13
REVIEW
Russell Maxwell, Christopher M Jackson, Michael Lim
Immune checkpoint inhibitors have changed the landscape of cancer immunotherapy and are being integrated into the standard of care for a variety of solid and hematologic malignancies. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries a grave prognosis despite advances in surgical resection, chemotherapy, and radiation therapy. Implementing immunotherapy for brain tumors mandates additional considerations due to the unique structural and immunologic milieu of the central nervous system (CNS)...
August 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28762020/conception-and-management-of-a-poorly-understood-spectrum-of-dermatologic-neoplasms-atypical-fibroxanthoma-pleomorphic-dermal-sarcoma-and-undifferentiated-pleomorphic-sarcoma
#14
REVIEW
Teo Soleymani, S Tyler Hollmig
Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) tumors share many clinical, etiologic, and histologic features and likely represent components of a tumor spectrum. In dermatologic oncology, differentiating between AFX and PDS is pivotal as tumors with histological features consistent with PDS are more likely to behave in a clinically aggressive manner. Importantly, the term "pleomorphic dermal sarcoma" (PDS) is a more appropriate designation than "undifferentiated pleomorphic sarcoma" (UPS) for describing deeper, more aggressive, histologically high-grade cutaneous tumors that otherwise resemble AFX...
August 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28681210/sebaceous-carcinoma-a-review-of-the-scientific-literature
#15
REVIEW
Thomas Knackstedt, Faramarz H Samie
Sebaceous carcinoma is a rare and potentially aggressive cutaneous malignancy. Commonly reported in the periocular area and the head and neck region, sebaceous carcinoma can arise from any sebaceous gland in the skin. The clinical presentation may be nonspecific, and a biopsy is important to establish a diagnosis and to differentiate from mimickers including benign sebaceous neoplasms, other adnexal tumors, and basal cell carcinoma. A diagnosis of Muir Torre syndrome should be considered in patients presenting with a sebaceous neoplasm...
August 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28681209/microcystic-adnexal-carcinoma-and-a-summary-of-other-rare-malignant-adnexal-tumours
#16
REVIEW
Arif Aslam
Microcystic adnexal carcinoma (MAC) is a rare, slow-growing, infiltrative malignant tumour most commonly found on the head and neck. It often presents as a solitary skin-coloured or yellow papule, plaque or nodule. Ultraviolet radiation, immunosuppression and ionising radiation are possible risk factors. Clinical and histological differential diagnoses include morpheaform basal cell carcinoma and desmoplastic trichoepithelioma. The diagnosis is usually made by skin biopsy, and the characteristic features are small keratin-filled cysts with nests and cords which resemble ductal structures...
August 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28681208/surgical-considerations-in-the-optimal-management-of-patients-with-malignant-brain-tumors
#17
REVIEW
Jaclyn J Renfrow, Roy E Strowd, Adrian W Laxton, Stephen B Tatter, Carol P Geer, Glenn J Lesser
Advances in technology are revolutionizing medicine and the limits of what we can offer to our patients. In neurosurgery, technology continues to reduce morbidity, increase surgical accuracy, facilitate tissue acquisition, and promote novel techniques for prolonging survival in patients with neuro-oncologic disease. Surgery has been the backbone of glioma diagnosis and treatment by providing adequate, high quality material for precise histologic diagnosis, and genomic characterization in the setting of significant intratumoral heterogeneity, thus allowing personalized treatment selection in the clinic...
August 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28681207/optimal-therapy-of-advanced-stage-mesothelioma
#18
REVIEW
Maria M J Disselhorst, Sjaak J A Burgers, Paul Baas
The optimal treatment of patients with advanced malignant pleural mesothelioma (MPM) has not yet been discovered. With the aid of an increased insight in the molecular pathways and the development of combinations of Immuno-Oncology (IO), drugs new therapies are available. The personalization of treatment by cell cultures and pathway analysis attracts more attention nowadays. It is conceivable that in the near future the treatment of patients with MPM will consist of a combination of IO drugs or specific pathway inhibitors...
August 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28670664/clinical-impact-of-the-2016-update-to-the-who-lymphoma-classification
#19
REVIEW
Ryan C Lynch, Dita Gratzinger, Ranjana H Advani
The 2016 revision of the WHO classification of lymphoid neoplasms includes new entities along with a clearer definition of provisional and definitive subtypes based on better understanding of the molecular drivers of lymphomas. These changes impact current treatment paradigms and provide a framework for future clinical trials. Additionally, this update recognizes several premalignant or predominantly indolent entities and underscores the importance of avoiding unnecessarily aggressive treatment in the latter subsets...
July 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28660602/immunotherapeutic-approaches-to-biliary-cancer
#20
REVIEW
Urvi A Shah, Amara G Nandikolla, Lakshmi Rajdev
Biliary tract cancers (BTCs) are rare aggressive neoplasms with a poor prognosis and a median survival of less than 1 year in the locally advanced or metastatic setting. Among the few patients who undergo curative resection the recurrence rates are high. About 90% of patients are detected at advanced stages, and systemic chemotherapy is the mainstay of their treatment. The treatment options for these patients are limited and multiple modalities of therapy from targeted therapy to immunotherapy and combination therapies (immunotherapy, targeted therapy, and chemotherapy) have been tested in this disease...
July 2017: Current Treatment Options in Oncology
journal
journal
34852
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"